Search Results
Jun 24, 2026, 10:00 ET New York City Regional Center-Managed Entity Provides Funding for 12ᵗʰ Public Charter School in New York City
Community Development ("NYCR-CDE"), a community development entity managed by NYCRC. To receive a New Markets Tax Credit allocation award, NYCR-CDE was required to demonstrate a mission and track record of providing investment capital for low-income communities.Since 2016, NYCR-CDE has received eight
More news about: New York City Regional Center
Jun 22, 2026, 20:00 ET AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation
Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and Index Case designation by the Taiwan Center for Drug Evaluation (CDE).
More news about: AnHorn Medicines
Jun 22, 2026, 15:07 ET SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for iza-bren (BL-B01D1) for the treatment of patients with recurrent or metastatic nasopharyngeal
More news about: SystImmune, Inc.
Jun 20, 2026, 20:52 ET CureGene Achieves First Participant Dosed in U.S. Pivotal Trial for Evategrel (CG-0255), a Best-in-Class Antiplatelet Drug, Accelerating Global Commercialization
therapy."Beyond the U.S., Evategrel is also advancing efficiently in China. The company has received clinical trial approval from the Center for Drug Evaluation (CDE) of China, and a Phase II trial for ischemic stroke is set to launch soon. The synchronized development in both China and the U.S. supports future simultaneous
More news about: CureGene
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
obtained FDA Fast Track Designation for three indications, Orphan Drug Designation for one indication, and Breakthrough Therapy Designation from the CDE of NMPA for two indications.Interim analysis for the Phase III clinical trials of urothelial carcinoma (UC) monotherapy, UC combination therapy
More news about: Mabwell
Jun 11, 2026, 21:57 ET Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
supplemental New Drug Application (sNDA) for gumokimab in active ankylosing spondylitis has been accepted for review by the Center for Drug Evaluation (CDE) of the NMPA.About AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing
More news about: Akeso, Inc.
Jun 10, 2026, 08:55 ET NYSE Content Update: ERock Sees $5.9 Billion Market Cap after its IPO Prices
roundOpening BellERock (NYSE: EROC) celebrates its IPOClosing BellCouer Mining (NYSE: CDE) celebrates its recent acquisition of New Gold Inc.For market insights, IPO activity, and today's opening bell, download the NYSE TV App:
More news about: New York Stock Exchange
Jun 05, 2026, 19:25 ET Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Coeur MiningCDEMaterials
More news about: S&P Dow Jones Indices
Jun 04, 2026, 04:19 ET Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
had received at least two prior lines of treatment, rocbrutinib was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) in May 2024. The corresponding pivotal Phase II registration study (ROCK-2) had already been initiated by the end of 2025.Results from a Phase
More news about: Lupeng Pharmaceutical Ltd
Jun 03, 2026, 06:00 ET ElpasBio Completes Patient Enrollment in Phase III Pivotal Clinical Trial of AlloJoin®
KOA.ElpasBio plans to read out the data from the Phase III pivotal study in 2027 and submit a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China later the same year.Tony (Bizuo) Liu, Chairman of ElpasBio, stated, "We sincerely
More news about: ElpasBio Holdings
Jun 01, 2026, 13:38 ET Banco Rendimento amplia atuação internacional com conta exclusiva para brasileiros e estrangeiros não residentes
Pix, oferecendo estrutura formal para movimentação de recursos e maior eficiência em operações de câmbio.Entre os principais diferenciais da CDE estão:Abertura 100% online e de maneira rápida;Remessas internacionais com cotação competitiva;Envio e recebimento
More news about: Rendimento
Jun 01, 2026, 11:00 ET Novogradac to Honor 16 CDEs for Community Development Investment Efforts at Upcoming Spring New Markets Tax Credit Conference
homes and 100 for-sale homes. The development received $43.8 million in combined QLICIs from six CDEs: Cinnaire New Markets LLC; MBS Urban Initiatives CDE LLC; Capital One Community Renewal Fund; Urban Action Community Development LLC; DV Community Investment LLC; and Grow America/HEDC New Markets Inc.The
More news about: Novogradac & Company LLP
May 31, 2026, 20:15 ET Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
with a primary focus on gastric/gastroesophageal junction adenocarcinoma (G/GEJA) and pancreatic cancer (PC).The Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satri-cel for the treatment of Claudin18.2-positive
More news about: CARsgen Therapeutics
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
months.Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published
More news about: Dizal Pharmaceutical
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
hematological malignancies indications, today announced that following review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), the company has received CDE endorsement to conduct the pivotal Phase III CLINCH-3 study of ATG-022, a Claudin 18.2 (CLDN18.2) antibody-drug
More news about: Antengene Corporation Limited
May 27, 2026, 09:20 ET Silver Above $75 An Ounce And A Cobalt Camp Consolidator Just Engaged The Original Authors Of Its NI 43-101 To Build A New Resource Estimate
(OTCQB: CCWOF) (FSE: QN3), Hecla Mining Company (NYSE: HL), First Majestic Silver Corp. (NYSE: AG), Coeur Mining, Inc. (NYSE: CDE), and Endeavour Silver Corp. (NYSE: EXK) collectively span the spectrum from emerging-stage Cobalt Camp consolidator to established mid-tier producer
More news about: Fly On Wall Street
May 27, 2026, 07:00 ET Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
and S HBV surface antigens, designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the "CDE") of China's National Medical Products Administration (the "NMPA") granted BRII-179 Breakthrough Therapy Designation.About ElebsiranElebsiran
More news about: Brii Biosciences Limited
May 27, 2026, 06:40 ET Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted and granted priority review to the New Drug Application (NDA) for ZEGFROVY®
More news about: Dizal Pharmaceutical
May 21, 2026, 23:30 ET Mabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
obtained FDA Fast Track Designation for three indications, Orphan Drug Designation for one indication, and Breakthrough Therapy Designation from the CDE of NMPA for two indications.Interim analysis for the Phase III clinical trials of urothelial carcinoma (UC) monotherapy, UC combination therapy
More news about: Mabwell
May 21, 2026, 10:04 ET Kelun-Biotech Announces Phase III Trial of Sacituzumab Tirumotecan (sac-TMT) versus Chemotherapy as First‑line Treatment for Advanced TNBC Met Primary Endpoint of PFS
safety signals were observed. Based on the results from the interim analysis, the Company plans to communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China regarding the subsequent regulatory pathway for sac‑TMT in this indication.This is
More news about: Kelun-Biotech
May 21, 2026, 10:00 ET Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Application (NDA) for relapsed or refractory mantle cell lymphoma (R/R MCL) has been accepted and is under Priority Review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Additionally, rocbrutinib has received Breakthrough Therapy Designation (BTD) in China for adult
More news about: Lupeng Pharmaceutical Ltd
May 18, 2026, 21:35 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a pivotal Phase III clinical trial for the first-line treatment of advanced extrapulmonary
More news about: Nanjing Leads Biolabs Co., Ltd.
May 12, 2026, 20:00 ET 科倫博泰PD-1 x VEGF雙抗SKB118新藥臨床試驗申請獲CDE批准
View original content to download multimedia:https://www.prnewswire.com/apac/zh/news-releases/pd-1-x-vegfskb118cde-302769714.htmlSOURCE 科倫博泰
More news about: 科倫博泰
May 12, 2026, 20:00 ET Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody
More news about: Kelun-Biotech
May 11, 2026, 07:00 ET Leads Biolabs R&D Symposium: Platform Synergy and Multi-Mechanism Integration Reshape the Immuno-Oncology Landscape
garnered Breakthrough Therapy Designation (BTD) from the CDE, as well as Fast Track Designation (FTD) and Orphan Drug Designation (ODD) from the U.S. FDA, and ODD from the European Union. The Company expects to submit the BLA for LBL-024 to the CDE in Q3 2026. The approval of LBL-024 will signify a pivotal
More news about: Nanjing Leads Biolabs Co., Ltd.